The Socialist Party in Hungary has proposed an amendment to the State Assets Act in a bid to ensure that the government keeps its 25% stake in the country's biggest drug manufacturer, Richter Gedeon. The legislative changes would allow - and effectively force - it to buy back bonds convertible for Richter shares. The move has effectively ended recent speculation about Richter's future ownership after the government-controlled convertible bonds expire in September this year.
The Hungarian government sold its 25% stake in Richter in September 2004 through a convertible bond and it is up to it to decide whether the holders would receive cash or Richter shares when the convertible bonds expire. Provided the proposed legislation passes the Budapest Parliament, the state could continue to remain the biggest shareholder. To pass the bill the minority socialist government will require the support of some opposition Members of Parliament too.
Richter welcomed the proposal, saying that "the government keeping its stake in the company would ensure the stable ownership structure" necessary for the pharmaceutical manufacturer to continue its growth strategy. According to Richter spokeswoman Zsuzsa Beke, buying back the bonds could cost the government as much as 200 billion forint ($976.0 million). With the recently-introduced economic austerity program in Hungary, it is hard to see where this money would come from.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze